https://adisinsight.springer.com/trials/700202044?error=cookies_not_supported&code=9853d10e-ff6a-44d3-b9fa-d24e72267b97
A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone...
This pivotal trial is evaluating the efficacy and tolerability of cabozantinib [XL 184; Exelixis], compared with mitoxantrone plus prednisone, as second-line